Vimarsana
Biggest News Aggregation in the World

Gu Research Network News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Gu Research Network. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Gu Research Network Today - Breaking & Trending Today

First patient treated in the US-based prostate cancer imaging trial of Cu-64 SAR-bisPSMA - Vimarsana News

First patient treated in the US-based prostate cancer imaging trial of Cu-64 SAR-bisPSMA

Published: April 21, 2022

/PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the...

Source: prnewswire.com
Related Topics:
United StatesNew South WalesAlan TaylorLuke NordquistNational Cancer InstituteTechnology PlatformUrology Cancer CenterGu Research NetworkClarity PharmaceuticalsCancer Statistics CenterGu Research Network In OmahaAmerican Cancer SocietyBiochemically RecurrentEmission TomographyExecutive ChairmanTargeted Copper TheranosticsUrologic Medical OncologistTargeted Copper TheranosticCancer StatisticsMortality WorldwideCancer Society
First patient treated in the US-based prostate cancer imaging trial of Cu-64 SAR-bisPSMA - Vimarsana News

First patient treated in the US-based prostate cancer imaging trial of Cu-64 SAR-bisPSMA

Published: April 21, 2022

/PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the...

Source: prnewswire.com
Related Topics:
United StatesNew South WalesAlan TaylorLuke NordquistNational Cancer InstituteTechnology PlatformUrology Cancer CenterGu Research NetworkClarity PharmaceuticalsCancer Statistics CenterGu Research Network In OmahaAmerican Cancer SocietyBiochemically RecurrentEmission TomographyExecutive ChairmanTargeted Copper TheranosticsUrologic Medical OncologistTargeted Copper TheranosticCancer StatisticsMortality WorldwideCancer Society
Clarity's US-based Cu-64 SAR-bisPSMA trial in prostate cancer opens for recruitment - Vimarsana News

Clarity's US-based Cu-64 SAR-bisPSMA trial in prostate cancer opens for recruitment

Published: March 28, 2022

/PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the...

Source: prnewswire.com
Related Topics:
New South WalesUnited StatesAlan TaylorLuke NordquistClarity PharmaceuticalsGu Research NetworkNational Cancer InstituteTechnology PlatformCarolina Urologic Research CentrePrnewswire Clarity PharmaceuticalsUrology Cancer CenterBiochemically RecurrentEmission TomographyExecutive ChairmanMay ProceedTargeted Copper TheranosticsSurgical OncologyMedical DirectorLead Principal InvestigatorHealth Care Amp Hospitals Biotechnology Pharmaceuticals Medical Pharmaceuticals Clinical Trials Amp Medical Discoveries
New clinical trial collaboration for Cu-64 SAR-bisPSMA in prostate cancer - Vimarsana News

New clinical trial collaboration for Cu-64 SAR-bisPSMA in prostate cancer

Published: March 24, 2022

/PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the...

Source: prnewswire.com
Related Topics:
United StatesNew South WalesAlan TaylorLuke NordquistGu Research NetworkNational Cancer InstituteClarity PharmaceuticalsTechnology PlatformPrnewswire Clarity PharmaceuticalsGu Research Network In OmahaUrology Cancer CenterExecutive ChairmanTargeted Copper TheranosticsStudy May Proceed LetterUrologic Medical Oncologist